<i>nab</i>-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial.

Onco Targets Ther · 2017 · PMC5295788 · PMID 28203092

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

8 , 11 In this analysis of patients in Western Europe with metastatic pancreatic cancer, a survival difference of nearly 4 months was observed between the nab -paclitaxel plus gemcitabine and gemcitabine-alone arms; however, this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.